A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailabl
A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
대표청구항▼
What is claimed is: 1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition for delivering an active ingredient to a mucosal surface of a mammal, comprising: an effective amount of an active ingredient, a water insoluble, water-swellable cross-linked polycarb
What is claimed is: 1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition for delivering an active ingredient to a mucosal surface of a mammal, comprising: an effective amount of an active ingredient, a water insoluble, water-swellable cross-linked polycarboxylic polymer, which is polycarbophil and a water soluble polymer, wherein the active ingredient comprises desmopressin or prostaglandin E2 and the polymers are present in an amount in combination which enables the composition to become progressively hydrated to provide an extended release of the active ingredient over time. 2. The composition of claim 1, wherein the active ingredient is desmopressin and is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition, and the composition is formulated to deliver the desmopressin via the buccal cavity and the tablet gelifies or swells to avoid asphyxiation. 3. The composition of claim 1, wherein the active ingredient is prostaglandin E2 and is present in an amount of up to about 2 mg per unit dosage of the composition. 4. The composition of claim 3, wherein the amount of prostaglandin E2 is in an amount of up to about 0.5 mg per unit dosage of the composition. 5. The composition of claim 1, wherein the composition is formulated as a tablet for delivery of the active ingredient via the buccal, vaginal, nasal, or rectal cavity. 6. The composition of claim 1, wherein the water insoluble. water-swellable cross-linked polycarboxylic polymer is polycarbophil. 7. The composition of claim 1, wherein the tablet is formulated to gelify or swell to avoid asphyxiation. 8. The composition of claim 1, wherein said water soluble polymer is carbomer 974P. 9. The composition of claim 1, wherein the composition delivers active ingredients for at least 48 hours. 10. The composition of claim 1, wherein the composition delivers active ingredients for as much as 72 hours. 11. A method of delivering an active ingredient to a mucosal surface of a mammal, which comprises associating the active ingredient in a composition with a water insoluable, water-swellable cross-linked polycarboxylic polymer which is polycarbophil and a water soluble polymer, so that when the composition is administered to the mammal, the composition becomes progressively hydrated to provide an extended release of the active ingredient, wherein the active ingredient comprises desmopressin or prostaglandin E2. 12. The method of claim 11, wherein the active ingredient is prostaglandin E2 and is present in an amount of up to about 2 mg per unit dosage of composition. 13. The method of claim 12, wherein the amount of prostaglandin E2 is up to about 0.5 mg per unit dosage of the composition. 14. The method of claim 11, wherein the active ingredient is desmopressin and is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition and said composition is formulated for delivery via the buccal cavity.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (103)
Pitha Josef (Baltimore MD), Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives.
Cuca Robert C. (Edwardsville IL) Lienhop Keith S. (St. Charles MO) Riley ; Jr. Thomas C. (Ballwin MO) Levinson R. Saul (Chesterfield MO) Kirschner Mitchell I. (St. Louis MO), Bioadhesive pharmaceutical delivery system.
Britton Peter (1133 S. Martine Ave. Scotch Plains NJ 07076) Flanagan Patricia (765 S. River Rd. Naperville IL 60540) Hart William P. (47 Wellington Rd. Freehold NJ 07728) Linkin Deborah (315E Medalli, Bioerodible device for administering active ingredients.
Hale Ron L. (Woodside CA) Lu Amy (Los Altos CA) Solas Dennis (San Francisco CA) Selick Harold E. (Belmont CA) Oldenburg Kevin R. (Fremont CA) Zaffaroni Alejandro C. (Atherton CA), Compositions and methods for enhanced drug delivery.
Petit Serge,FRX ; Bourland ; deceased Emile,FRX ITX by Jacqueline Bourland ; legal representative, Compositions for delivery of polypeptides, and methods.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Larsson K.ang.re,SEX ; Ljusberg-Wahren Helena,SEX, Controlled release composition forming a reversed micellar (L2) structure or a normal micellar (L1) structure.
El-Rashidy Ragab (Deerfield IL) Ronsen Bruce (River Forest IL) Hassan Emad E. (Sidi Gaber EGX), Controlled release of drugs delivered by sublingual or buccal administration.
Sandow Jurgen (Glashutten/Taunus DEX) Durckheimer Walter (Hattersheim am Main DEX) Ditzinger Gunter (Frankfurt am Main DEX) Merkle Hans-Peter (Zurich CHX), Cyclopeptides and their use as absorption promoters when applied to the mucosa.
Larsson Krister (Malmo SEX) Mellbrand Thomas (Malmo SEX) Mornstam Birgitta (Bunkeflostrand SEX) Roschester Jan (Lund SEX) Skoldback Jan-Ake (Malmo SEX), High purity desmopressin produced in large single batches.
Ceschel Giancarlo (Milan ITX) Segu\ Antonella M. (Milan ITX) Ronchi Celestino (Milan ITX), Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient.
Dumoulin Yves,CAX ; Carriere Fran.cedilla.ois,CAX ; Ingenito Andre,CAX, Manufacture of cross-linked amylose useful as a excipient for control release of active compounds.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Britton Peter (1133 S. Martine Ave. Scotch Plains NJ 07076) Flanagan Patricia (765 S. River Rd. Naperville IL 60540) Hart William P. (47 Wellington Rd. Freehold NJ 07728) Linkin Deborah (315E Medalli, Method for manufacturing buccal delivery device.
Hostetler Karl Y. (Del Mar CA) Kumar Raj (San Diego CA), Method of converting a drug to an orally available form by covalently bonding a lipid to the drug.
Kensil Charlotte A. (Milford MA) Soltysik Sean (Worcester MA) Marciani Dante J. (Hopkinton MA), Methods for enhancing drug delivery with modified saponins.
Ebert Charles D. (Salt Lake City UT) Patel Dinesh C. (Murray UT) Mazer Norman A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT), Methods for providing testosterone and optionally estrogen replacement therapy to women.
Poli Stefano (Quinto de\Stampi-Rozzano ITX) Coppi Germano (Quinto de\Stampi-Rozzano ITX) Busetti Cesare (Quinto de\Stampi-Rozzano ITX), Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam.
Larsson Krister (MalmSEX) Mellbrand Thomas (MalmSEX) Mrnstam Birgitta (MalmSEX) Roschester Jan (Lund SEX) Skldbck Jan-Ake (Malm SEX), Process for manufacture of 1-deamino-8-D-arginine vasopressin.
Aiache Jean-Marc (17 rue Marchal Gallini 63000 Clermond-Ferrand FRX), Process for preparing a bioadhesive pharmaceutical dosage form and pharmaceutical dosage form thus prepared.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
Amidon, Gregory Everett; Ganorkar, Loksidh Devi; Heimlich, John Mark; Lee, Ernest J.; Noack, Robert Martin; Reo, Joseph Peter; Skoug, Connie Jo, Sustained-release tablet composition of pramipexole.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.